Market Research Report

Product code

666935

Immunoglobulin E (IgE) Allergy Blood Tests - Medical Devices Pipeline Assessment, 2019

Published: November 1, 2019 |

GlobalData | 68 Pages | Delivery time: 1-2 business days

Price

Description
Table of Contents
List of Tables

Add to Compare

GlobalData's Medical Devices sector report, "Immunoglobulin E (IgE) Allergy Blood Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Immunoglobulin E (IgE) Allergy Blood Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunoglobulin E (IgE) Allergy Blood Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Immunoglobulin E (IgE) Allergy Blood Tests under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Immunoglobulin E (IgE) Allergy Blood Tests and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry

Reasons to buy

The report enables you to -

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Immunoglobulin E (IgE) Allergy Blood Tests under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product's current stage of development, territory and estimated launch date

Product Code: GDME0810EPD

1 Table of Contents

1.1 List of Tables 4
1.2 List of Figures 5

2 Introduction 6

2.1 Immunoglobulin E (IgE) Allergy Blood Tests Overview 6

3 Products under Development 7

3.1 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Stage of Development 7
3.2 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Segment 8
3.3 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Territory 9
3.4 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Regulatory Path 10
3.5 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Estimated Approval Date 11

4 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products under Development by Companies 12

4.1 Immunoglobulin E (IgE) Allergy Blood Tests Companies - Pipeline Products by Stage of Development 12
4.2 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Stage of Development 13

5 Immunoglobulin E (IgE) Allergy Blood Tests Companies and Product Overview 14

5.1 Abionic SA Company Overview 14

5.1.1 Abionic SA Pipeline Products & Ongoing Clinical Trials Overview 14

5.2 Amerimmune LLC Company Overview 15

5.2.1 Amerimmune LLC Pipeline Products & Ongoing Clinical Trials Overview 15

5.3 AXO Science SAS Company Overview 17

5.3.1 AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 17

5.4 Biovator AB (Inactive) Company Overview 18

5.4.1 Biovator AB (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 18

5.5 Children's Hospital Boston Company Overview 19

5.5.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 19

5.6 China Medical Technologies Inc (Inactive) Company Overview 21

5.6.1 China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 21

5.7 Cytognos, SL Company Overview 22

5.7.1 Cytognos, SL Pipeline Products & Ongoing Clinical Trials Overview 22

5.8 EUROIMMUN US LLC Company Overview 23

5.8.1 EUROIMMUN US LLC Pipeline Products & Ongoing Clinical Trials Overview 23

5.9 Ferrer inCode SL Company Overview 25

5.9.1 Ferrer inCode SL Pipeline Products & Ongoing Clinical Trials Overview 25

5.10 HOB Biotech Group Suzhou Co Ltd Company Overview 26

5.10.1 HOB Biotech Group Suzhou Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

5.11 Hycor Biomedical Inc Company Overview 27

5.11.1 Hycor Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.12 Institut fur Produktqualitat GmbH Company Overview 29

5.12.1 Institut fur Produktqualitat GmbH Pipeline Products & Ongoing Clinical Trials Overview 29

5.13 IRCCS San Raffaele Hospital Company Overview 30

5.13.1 IRCCS San Raffaele Hospital Pipeline Products & Ongoing Clinical Trials Overview 30

5.14 Medical Research Council Company Overview 31

5.14.1 Medical Research Council Pipeline Products & Ongoing Clinical Trials Overview 31

5.15 Stanford University Company Overview 32

5.15.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 32

5.16 Thermo Fisher Scientific Inc Company Overview 33

5.16.1 Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 33

5.17 University of Connecticut Health Center Company Overview 34

5.17.1 University of Connecticut Health Center Pipeline Products & Ongoing Clinical Trials Overview 34

5.18 University of Nottingham Company Overview 35

5.18.1 University of Nottingham Pipeline Products & Ongoing Clinical Trials Overview 35

5.19 University of Queensland Company Overview 36

5.19.1 University of Queensland Pipeline Products & Ongoing Clinical Trials Overview 36

5.20 VEGA Ltd Company Overview 37

5.20.1 VEGA Ltd Pipeline Products & Ongoing Clinical Trials Overview 37

6 Immunoglobulin E (IgE) Allergy Blood Tests - Recent Developments 38

6.1 Sep 24, 2019: Theradiag announces improved results for H1 2019 38
6.2 Sep 05, 2019: Thermo Fisher Scientific elects New Director to Board 40
6.3 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 41
6.4 Jul 29, 2019: Siemens Healthineers continues to drive growth forward 41
6.5 Jul 29, 2019: Changes in the Managing Board of Siemens Healthineers 43
6.6 Jul 29, 2019: OBN announce Thermo Fisher Scientific as a new Corporate Sponsor 43
6.7 Jul 24, 2019: Thermo Fisher Scientific reports second quarter 2019 results 44
6.8 Jul 18, 2019: Theradiag announces first-half revenue up 9% 46
6.9 Jul 01, 2019: Arrayit approved for Electronic Medicare Reimbursement from the Centers for Medicare and Medicaid Services 47
6.10 May 17, 2019: SenzaGen receives new order of SEK 0.5 m from a recurring customer 47
6.11 May 02, 2019: Siemens Healthineers posts strong revenue and profit growth in the second quarter 48
6.12 May 02, 2019: New method to analyze blood shows immune cell rare; likely not involved in food allergy 49
6.13 Apr 24, 2019: Thermo Fisher Scientific announces first quarter 2019 results 50
6.14 Apr 04, 2019: Theradiag and HOB Biotech settle their legal dispute 51
6.15 Mar 27, 2019: Theradiag reports its 2018 full-year results 52
6.16 Feb 25, 2019: Thermo Fisher Scientific launches new dosimetry monitoring service 53
6.17 Feb 20, 2019: Theradiag reports annual revenues for 2018 and its year-end cash position 54
6.18 Feb 11, 2019: Siemens Healthineers to invest EUR 350 million in new Campus Forchheim 54
6.19 Jan 30, 2019: Thermo Fisher Scientific reports fourth quarter and full year 2018 results 55
6.20 Jan 28, 2019: Arrayit allergy testing services endorsed by leading Pediatrics Medical Group 58
6.21 Dec 11, 2018: TheraDiag names Bertrand de Castelnau as Chief Executive Officer 58
6.22 Dec 04, 2018: 10 Billion Lab Tests and Growing: Siemens Healthineers Mass. Manufacturing Expansion Largely Completed 59
6.23 Dec 04, 2018: 10 billion lab tests and growing: Siemens Healthineers mass. Manufacturing expansion largely completed 60
6.24 Nov 19, 2018: Arrayit announces allergy testing agreement with Sutter Health 61
6.25 Nov 07, 2018: Thermo Fisher Scientific names Jim Mullen to its board of directors 61
6.26 Nov 05, 2018: Siemens Healthineers with strong finish in fourth quarter, full year targets for fiscal 2018 achieved 62
6.27 Oct 31, 2018: Appointment of Pierre Morgon as chairman of the board of directors of Theradiag 63

7 Appendix 65

7.1 Methodology 65
7.2 About GlobalData 68
7.3 Contact Us 68
7.4 Disclaimer 68

List of Tables

Table 1: Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Stage of Development 7
Table 2: Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Segment 8
Table 3: Immunoglobulin E (IgE) Allergy Blood Tests - Pip

List of Figures

Figure 1: Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Stage of Development 7
Figure 2: Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Segment 8
Figure 3: Immunoglobulin E (IgE) Allergy Blood Tests -